Blog
SS-31 vs. MOTS-c: How Their Research Roles Differ
SS-31 and MOTS-c frequently appear together in discussions about mitochondria, cellular energy, and physical function. But sharing a connection to mitochondria does not make them interchangeable.
The main SS-31 vs. MOTS-c differences concern where their research begins: SS-31 has been investigated for interactions with the mitochondrial membrane and energy-producing machinery, while MOTS-c has attracted attention as a signaling peptide involved in metabolic regulation and cellular adaptation.
Both offer reasons for continued investigation. Understanding their distinct roles helps readers, ingredient buyers, and development teams see what makes each material interesting—and which findings actually support that interest.
SS-31 vs. MOTS-c at a Glance
| Comparison | SS-31 | MOTS-c |
|---|---|---|
| Identity | Synthetic four-amino-acid peptide, also known as elamipretide | A 16-amino-acid mitochondrial-derived peptide; synthetic material is used in experiments |
| Mitochondrial connection | Interactions with cardiolipin in the inner mitochondrial membrane | Signaling associated with metabolism and stress adaptation |
| Representative research focus | Electron transport, ATP production, mitochondrial structure, and muscle function | Insulin sensitivity, metabolic signaling, exercise-related responses, and physical performance |
| Human evidence | Interventional studies involving specific populations and pharmaceutical preparations | Studies of endogenous levels and physiological responses; administered native-peptide efficacy remains unestablished |
| Clinical development | Forzinity, an elamipretide medicine, has a specific FDA-approved indication | Native MOTS-c must be distinguished from development analogues |
| Main comparison limitation | Findings depend on the population, endpoint, and product studied | Natural peptide measurements do not establish benefits from administering synthetic material |
These distinctions draw on original mechanistic studies, human research, and FDA materials discussed below. They describe different evidence bases rather than a universal ranking.
Different Mechanisms, Different Research Questions
SS-31: Cardiolipin and Mitochondrial Function
Cardiolipin is a lipid concentrated in the inner mitochondrial membrane. That membrane houses much of the machinery responsible for producing ATP, a molecule cells use to transfer energy.
Experiments using membrane systems and isolated mitochondria found that SS-31 interacted with cardiolipin, influenced its relationship with the electron-carrying protein cytochrome c, and improved measures of respiration and ATP synthesis. These findings provide a specific biochemical foundation for investigating mitochondrial performance. [1]
The research question is practical: can influencing the environment around energy-producing machinery improve how it functions?
MOTS-c: Metabolic Signaling and Cellular Adaptation
MOTS-c brings a different perspective. Mitochondria participate in cellular communication as well as energy production.
A 2018 study found that MOTS-c moved into the nucleus during metabolic stress and influenced gene expression through processes involving AMPK, an important energy-sensing regulator. This connects MOTS-c research to how cells adjust their behavior when resources or conditions change. [2]
Its research question is therefore broader than increasing energy output: can a mitochondrial-derived signal influence how cells manage metabolic demands and stress?
The distinction helps explain why the two peptides attract overlapping interest without necessarily serving the same experimental purpose.
How Do Their Potential Benefits Compare?
Cellular Energy: Production Capacity and Metabolic Adaptation
SS-31 has a particularly direct connection to mitochondrial bioenergetics—the processes involved in producing usable cellular energy.
Beyond the membrane experiments, a randomized human study investigated elamipretide in 39 adults aged 60–85, selected for reduced mitochondrial function. Following a single administration, the relative change in maximal mitochondrial ATP-production capacity favored elamipretide over placebo.
The statistical detail matters: the relative-change analysis reached significance, while the absolute-change analysis narrowly missed the conventional threshold. The study found no significant improvement in the tested muscle’s fatigue resistance. This makes the result an encouraging physiological finding rather than proof of greater everyday energy. [3]
MOTS-c research emphasizes metabolic adjustment. Its interest lies in how cells regulate fuel handling and respond to changing demands, making metabolic endpoints especially relevant when evaluating its potential.
Muscle Function and Exercise: Different Positive Findings
For SS-31, muscle function has become a clinically important development area. Its pharmaceutical form has reached an approved use involving muscle strength in a specific mitochondrial disease population.
MOTS-c has produced notable animal performance findings. A 2021 study reported improved physical performance in young, middle-aged, and old mice receiving MOTS-c. The researchers also investigated skeletal-muscle metabolism and cellular adaptation to metabolic stress. [4]
These findings make both materials relevant to muscle-related development questions, but the outcomes differ:
- Muscle strength measures force.
- Endurance measures sustained performance.
- Walking or treadmill performance combines several physiological functions.
- Cellular energy capacity measures a biological process underlying function.
Keeping these outcomes separate makes the advantages of each research program clearer.
Metabolic Regulation: A Central Strength of MOTS-c Research
A foundational 2015 study connected MOTS-c activity to the folate–purine–AMPK pathway and skeletal-muscle metabolism. In mice, treatment protected against age-related and high-fat-diet-induced insulin resistance, as well as diet-induced obesity. [5]
These results explain why MOTS-c remains interesting for projects investigating glucose regulation, nutrient handling, and metabolic dysfunction.
SS-31’s membrane-focused research asks a related but distinct question about mitochondrial performance. Improvements in energy-producing machinery and changes in metabolic regulation can interact biologically, but they are not identical experimental outcomes.
For development teams, that distinction helps define which material fits the question being investigated.
Age-Related Function: Promising Directions, Different Evidence
Age-related research adds another reason for interest.
The older-adult elamipretide trial examined a measurable aspect of mitochondrial capacity. MOTS-c experiments explored physical function across mouse age groups, including late-life intervention.
These approaches help investigate how biological function changes with age. Neither establishes longer human lifespan or a general reversal of aging.
Human Evidence: Are We Comparing the Same Things?
Elamipretide Has a Defined Pharmaceutical Development Record
On September 19, 2025, the FDA granted accelerated approval to Forzinity (elamipretide) to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg.
The approval was based on improvement in knee extensor strength, considered reasonably likely to predict clinical benefit. A confirmatory trial is required to verify that benefit. [6]
The supporting study enrolled 12 participants. Its randomized crossover portion did not demonstrate superiority over placebo on the primary walking-distance and fatigue endpoints. Muscle-strength increases were observed during the subsequent open-label extension, which has different interpretive limitations from a blinded comparison. [7]
This is a meaningful development milestone with a specific scope. It does not confer approval on other SS-31 products or establish benefits for healthy consumers.
Human MOTS-c Measurements and Administered MOTS-c Are Different Evidence
The 2021 exercise study also reported changes in naturally occurring MOTS-c in human skeletal muscle and circulation following exercise. That supports interest in its physiological role, while remaining distinct from testing synthetic MOTS-c as an intervention. [4]
In materials for its July 2026 advisory meeting, the FDA reported that it had not identified publicly available clinical studies evaluating administration of the MOTS-c-related bulk substances under review to humans. This article’s search likewise did not identify published controlled efficacy results establishing benefits from administered native MOTS-c. [8]
Related analogues require separate treatment. CB4211, developed as an analogue of MOTS-c, underwent a human development program with sponsor-reported results. Those findings concern a different compound and cannot be transferred directly to native MOTS-c. [9]
A registered study describes a research plan. Published findings or disclosed results describe what that research actually observed.
A Practical Evidence Comparison
| Evidence category | SS-31-related evidence | MOTS-c-related evidence | Interpretation |
|---|---|---|---|
| Laboratory and animal studies | Membrane interactions and mitochondrial-function experiments | Metabolic signaling, stress-response, and performance experiments | Explain biological potential |
| Human physiological research | Intervention measuring mitochondrial capacity in selected older adults | Measurements of endogenous peptide responses | These test different questions |
| Human clinical development | Disease-specific interventional studies and an approved elamipretide medicine | Native-peptide evidence must remain separate from analogue programs | Compare actual materials and outcomes |
| Product relevance | Pharmaceutical findings apply to the tested preparation and conditions | Experimental findings apply to the studied material and model | A shared name does not establish product equivalence |
“Repair First, Then Stimulate”: What Supports This Claim?
The analogy presents SS-31 as preparing mitochondrial machinery and MOTS-c as activating metabolic responses afterward.
It is memorable, but it compresses complex biology into two steps. “Repair” and “stimulate” are not standardized clinical endpoints, and neither establishes that one peptide must precede the other.
This review did not identify a published human study directly testing:
- SS-31 against MOTS-c.
- Their combination against either material alone.
- SS-31 followed by MOTS-c against the reverse sequence.
Each would require its own study design, measurements, and safety assessment.
The mechanisms provide a reason to ask combination questions. They do not establish combination benefits, an optimal sequence, or a validated protocol.
Can One Replace the Other?
Substitution depends on the intended research question.
A project focused on cardiolipin-associated mitochondrial function has a different starting point from one examining metabolic signaling or adaptation to nutrient stress.
For buyers and development teams, the useful comparison is therefore:
Intended endpoint → relevant mechanism → supporting model or population → actual material
This is more informative than choosing between two ingredients because both appear under the label “mitochondrial peptides.”
Frequently Asked Questions
Are SS-31 and MOTS-c the Same Type of Material?
Both are peptides associated with mitochondrial research, but their structures, biological backgrounds, and investigated roles differ.
Which Has More Human Research?
Elamipretide has the more developed human interventional and pharmaceutical record. That does not establish superiority for every proposed application.
Has Either Been Proven to Improve Everyday Energy?
The evidence discussed here does not establish a general benefit for ordinary tiredness in healthy people. ATP capacity, disease-related function, and subjective energy are different outcomes.
Does Research on Each Compound Prove They Work Better Together?
No. Individual findings can motivate a combination study, but the combination must be evaluated directly.
Compare the Research Question, Not Just the Category
SS-31 and MOTS-c offer distinct reasons for continued investigation.
SS-31 connects membrane-focused biology with mitochondrial-function studies and a substantial pharmaceutical development history. MOTS-c connects mitochondrial signaling with metabolic regulation, stress adaptation, and encouraging animal performance findings.
For businesses evaluating these materials, understanding that distinction helps define a clearer development objective and a more accurate product proposition.
Explore Novacybio’s SS-31 and MOTS-c product specifications, or contact us to discuss bulk purchasing, raw material requirements, and business procurement.
References
- Birk AV, et al. Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. British Journal of Pharmacology. 2014;171(8):2017–2028. DOI: 10.1111/bph.12468.
- Kim KH, Son JM, Benayoun BA, Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metabolism. 2018;28(3):516–524.e7. DOI: 10.1016/j.cmet.2018.06.008.
- Roshanravan B, et al. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial. PLOS ONE. 2021;16(7):e0253849. DOI: 10.1371/journal.pone.0253849. PMID: 34264994.
- Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12:470. DOI: 10.1038/s41467-020-20790-0.
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443–454. DOI: 10.1016/j.cmet.2015.02.009.
- U.S. Food and Drug Administration. FDA Grants Accelerated Approval to First Treatment for Barth Syndrome. September 19, 2025.
- U.S. Food and Drug Administration. Drug Trials Snapshots: Forzinity. Summary of the studies supporting the original September 19, 2025 approval.
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting Materials: MOTS-c-related Bulk Drug Substances. July 23–24, 2026; MOTS-c presentation within the meeting slide deck.
- CohBar, Inc. Breakthrough Mitochondrial Science: A Source for Novel Therapeutics. September 2021 corporate presentation, filed with the U.S. Securities and Exchange Commission as Exhibit 99.1. Sponsor-reported information.